Zivo Bioscience Inc (OTCQB: ZIVO) is a biotechnology and bioactive ingredients company developing algal biomass-derived products for animal health and human nutrition applications. The company generates no commercial revenue as of FY2024, operating entirely on capital raises to fund research and development of its product candidates. Zivo's primary focus is a non-antibiotic coccidiosis treatment candidate for broiler chickens, alongside additional programs targeting companion animal health, skin health ingredients, and dietary supplement applications. The algal biomass has received self-affirmed GRAS status, updated in May 2023, validating suitability as a safe ingredient for human consumption. Zivo's contract manufacturer for algae products is located in Peru. The company leases approximately 3,200 square feet of principal office space in Troy, Michigan, and also operates a laboratory facility. With no product revenue and ongoing net losses through FY2024, Zivo is a pre-commercial stage company dependent on equity and debt financing. It is quoted on the OTCQB and classified as a non-accelerated filer under SEC rules.

Revenue model

Zivo has no commercial revenue as of FY2024. The company is pre-revenue, funding operations through private equity offerings and debt financing. Future revenue, if any, would derive from product sales, licensing, or collaborative arrangements tied to regulatory approval of its product candidates.

Products and services

Primary product candidate: non-antibiotic algal biomass-based coccidiosis treatment for broiler chickens, targeting prevention of Eimeria parasite-driven gut disease. Additional programs include companion animal food ingredients, skin health topical and ingestible products, and a New Dietary Ingredient (NDI) pathway for human dietary supplements. The algal biomass carries self-affirmed GRAS status updated May 2023. Zivo also holds patents and patent applications related to Variovorax microbes as a coccidiostat across multiple jurisdictions including the US, EU, Canada, Australia, Japan, China, Brazil, Russia, Peru, and others.

Customers and end markets

Target end markets include the poultry industry (broiler chicken producers), companion animal health, and human nutrition and skin health. Relevant global market sizes cited in the FY2024 10-K: animal health vaccines $13.7 billion (2023), phytogenics $1.1 billion (2023), eubiotics $5.1 billion (2024), and companion animal drugs $19.6 billion. No commercial customers as of the filing date.

Value-chain role

Zivo is a pre-commercial biotech developer positioned upstream in the animal health and nutrition supply chain. It conducts research and development internally and through third-party contractors, with contract manufacturing of algae products outsourced to a facility in Peru. Zivo does not manufacture at scale or distribute commercial products as of FY2024.

Geographic exposure

Principal operations in Troy, Michigan (office) and an undisclosed laboratory facility. Contract manufacturing in Peru. Patent prosecution active across the US, Canada, Europe, Australia, Japan, China, Brazil, Russia, South Africa, New Zealand, and Peru as of the FY2024 10-K filing.

Source: SEC 10-K, filed 2025-03-18

Industry: Biological Products, (No Diagnostic Substances) Peers: Fuss Brands Corp. MAKINGORG, INC. Estee Lauder Companies Inc High Sierra Technologies, Inc. LifeVantage Corp Mannatech Inc TWINLAB CONSOLIDATED HOLDINGS, INC. Natural Alternatives International Inc